Quarterly ResultAug 6, 2026, 04:26 PM
Zentalis Q2 Net Loss $(42.3)M; $7M Milestone for Phase 3 Trial
AI Summary
Zentalis Pharmaceuticals reported a net loss of $(42.3) million for Q2 2026 and $(77.6) million for the six months ended June 30, 2026, an increase from the prior year. The company incurred a $7.0 million milestone payment for the commencement of its Phase 3 ASPENOVA clinical trial for azenosertib. Zentalis continues to operate with significant net losses and had $174.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, indicating a need for additional capital beyond one year.
Key Highlights
- Net loss for Q2 2026 was $(42.3) million, compared to $(26.9) million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $(77.6) million, up from $(75.2) million in H1 2025.
- Paid a $7.0 million milestone for the commencement of the Phase 3 ASPENOVA clinical trial for azenosertib.
- Research and development expenses increased to $63.9 million for H1 2026 from $54.9 million in H1 2025.
- Cash, cash equivalents, and marketable securities totaled $174.6 million as of June 30, 2026.
- Accumulated deficit reached $(1.3) billion as of June 30, 2026.
- Net cash used in operating activities was $(70.2) million for the six months ended June 30, 2026.
Price Impact
More from ZNTL